XDx, Inc. and LabCorp Enter Into Collaboration and License Agreement to Develop Lupus Flare Predictor Test

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc. announced today that it has entered into a collaboration and license agreement with Laboratory Corporation of America® Holdings (LabCorp) (NYSE: LH) whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). The agreement combines XDx’s autoimmune diagnostics research and discovery experience and SLE blood sample database with LabCorp’s diagnostic development and commercialization resources. Financial terms of the agreement were not disclosed.